Support for Regulated Psychedelic Therapy and Research Rises Sharply in U.S. Poll

A new national survey by the University of California, Berkeley Center for the Science of Psychedelics (BCSP) reveals a significant shift in American attitudes toward psychedelic therapies and research. According to the poll, support for legal, regulated access to psychedelics for therapeutic purposes has increased markedly over the past two years, reflecting growing public openness to alternative mental health treatments. The survey, conducted in April 2025, included responses from 1,577 U.S. voters and carries a margin of error of +/-2.5 percentage points

The data show that support for making psychedelics available by prescription jumped from 29 percent in 2023 to 41 percent in 2025, a 12-point increase. Likewise, approval for legal therapeutic use rose from 36 percent to 46 percent during the same period. Notably, support for expanding scientific research into psychedelics surged to 63 percent, up from 49 percent two years prior. The BCSP report observes, “Voters appear to be warming up to psychedelics as medical treatments accessed within regulated medical and therapeutic frameworks.”

Despite these gains, the survey found that public enthusiasm for decriminalizing psychedelics remains limited. Only 28 percent of respondents backed removing criminal penalties for personal use and possession—a stark contrast to the broad support decriminalization has long enjoyed in the context of marijuana policy. The report suggests that while voters are increasingly curious about the medical potential of psychedelics, concerns about safety and efficacy persist. “Despite an increase in local legislation that decriminalizes personal possession, we observed only tepid support from voters for this kind of policy,” the authors noted

Support for regulated therapeutic access was notably higher for specific groups, such as military veterans (56 percent), individuals with depression (60 percent), and people experiencing addiction (54 percent). When it comes to end-of-life care, 48 percent favored regulated access and 38 percent supported decriminalization. However, perceptions of safety remain cautious: 37 percent of respondents viewed supervised psychedelic use as 'pretty' or 'extremely' safe, while a smaller share believed psychedelics are safer than tobacco (20 percent) or alcohol (18 percent)

The evolving landscape is also reflected in federal policy developments. In recent months, a bipartisan group of lawmakers has called on health agencies to expedite reviews of psychedelic therapies, and the FDA and HHS have announced new measures to accelerate therapeutic access for patients with severe mental health conditions. HHS Secretary Robert F. Kennedy Jr. emphasized the administration’s commitment, stating that officials are 'very anxious' to establish pathways for psychedelic therapy, particularly for veterans and those with PTSD or depression. Congress is also considering legislation to fund 'centers for excellence' at VA facilities to expand access for veterans

From the OG Lab newsroom perspective, this surge in support for regulated psychedelic therapy and research could reshape the mental health landscape in the United States. The public’s preference for controlled, evidence-based frameworks over broad decriminalization highlights a cautious but growing trust in these substances’ therapeutic potential. As policy momentum builds and research advances, stakeholders in both the cannabis and psychedelics sectors should watch closely for regulatory shifts and new opportunities in the alternative medicine market